肌少症可能增加肾功能临界膀胱癌患者的顺铂毒性
本研究纳入2010至2022年间接受根治性膀胱切除术且新辅助化疗前有影像的216例肌层浸润性膀胱癌患者,评估肌少症对新辅助化疗毒性的影响是否受肾功能临界(eGFR 40-65 mL/min)修饰。结果显示肌少症与肾相关新辅助化疗毒性风险显著相关(OR 4.88,95%CI 1.65-14.44;P=0.004),在肾功能临界患者中肌少症的肾毒性OR为8.46(95%CI 1.06-67.72),正常肾功能者为3.11(95%CI 0.81-11.88),交互作用P=0.43。结论认为肌少症与更高的肾毒性 odds 相关,并可能在肾功能临界患者中增加肾毒性风险。
要点
- 216例肌层浸润性膀胱癌患者中83%存在肌少症,76%接受吉西他滨/顺铂新辅助化疗。
- 未调整模型中肌少症与肾相关新辅助化疗毒性显著相关(OR 4.88,95%CI 1.65-14.44;P=0.004)。
- 肾功能临界(eGFR 40-65 mL/min)患者中肌少症的肾毒性OR为8.46(95%CI 1.06-67.72),正常肾功能者为3.11(95%CI 0.81-11.88),交互作用P=0.43。
核心结论
- 在接受新辅助化疗的肌层浸润性膀胱癌患者中,肌少症与更高的新辅助化疗相关肾毒性 odds 相关,并可能在肾功能临界患者中增加肾毒性风险。
研究设计与样本
- 纳入2010至2022年间接受根治性膀胱切除术、且新辅助化疗开始前有可用横断面影像的肌层浸润性膀胱癌患者,共216例。
- 通过L3椎体水平轴位CT图像使用Aquarius Intuition软件测量骨骼肌质量,依据骨骼肌指数共识定义判定肌少症。
- 新辅助化疗毒性按常见不良事件评价标准第5.0版分级,采用二元逻辑回归识别新辅助化疗相关肾毒性的预测因素。
主要发现
- 216例患者中83%存在肌少症,76%接受吉西他滨/顺铂新辅助化疗。
- 未调整模型中,肌少症与肾相关新辅助化疗毒性显著相关(OR 4.88,95%CI 1.65-14.44;P=0.004)。
- 在评估肌少症与肾功能交互效应的模型中,eGFR 40-65 mL/min患者中肌少症的肾毒性OR为8.46(95%CI 1.06-67.72),正常肾功能患者为3.11(95%CI 0.81-11.88),交互作用P=0.43。
局限性
- 原文未报告局限性。
以上解读依据论文摘要(全文未开放获取或许可不允许翻译转载)。
原文
OBJECTIVES: To assess whether the effect of sarcopenia on neoadjuvant chemotherapy (NAC) toxicity is modified by borderline renal function (estimated glomerular filtration rate [eGFR] 40-65 mL/min) and whether sarcopenia and borderline renal function are independently associated with NAC toxicity risk. PATIENTS AND METHODS: All patients with muscle-invasive bladder cancer (MIBC) who underwent radical cystectomy (RC) between 2010 and 2022, with available cross-sectional imaging prior to NAC initiation, were included. Skeletal mass was measured from axial computed tomography images obtained at the level of the L3 vertebral body, using Aquarius Intuition software. Sarcopenia was assigned based on consensus definitions of skeletal mass index. NAC toxicity was graded according to Common Terminology Criteria for Adverse Events version 5.0. Binary logistic regression was used to identify the predictors of NAC-associated renal toxicity. RESULTS: A total of 216 patients were included. Most patients had sarcopenia (83%) and received gemcitabine/cisplatin NAC (76%). In an unadjusted model, sarcopenia was associated with a significant risk of renal-associated NAC toxicity (odds ratio [OR] 4.88, 95% confidence interval [CI] 1.65-14.44; P = 0.004). In an effect modification model evaluating the interaction between sarcopenia and renal function, the OR for renal toxicity with sarcopenia among patients with eGFR 40-65 mL/min was 8.46 (95% CI 1.06-67.72) vs 3.11 (95% CI 0.81-11.88) among patients with normal renal function (P = 0.43). CONCLUSION: Among MIBC patients who received NAC, sarcopenia was associated with higher odds of NAC-associated renal toxicity and may increase risk of renal toxicity among patients with borderline renal function.
引用
- Haile ES, Lone Z, Shin D, et al. Sarcopenia may increase cisplatin toxicity in bladder cancer patients with borderline renal function. BJU Int. 2024. PMID: 39654302. doi:10.1111/bju.16606
供执业医师工作参考,不替代临床判断;数值与分级以指南原文为准。